GMAB
Genmab A/S
NASDAQ · Healthcare · Biotechnology · DK
$33.60
−2.35%Aug 6, 2026, 18:04 UTC
Genmab announced two new Phase III studies of petosemtamab in colorectal cancer.
Source:Jun 30, 2026, 09:35 UTC
Genmab and AbbVie announced that their drug combination for lymphoma met the primary goal in a late-stage clinical trial.
Source: